Sun Pharma’s Profit Beats Estimates on Specialty Drug Push
(Bloomberg) -- Sun Pharmaceutical Industries Ltd., owned and run by billionaire Dilip Shangvhi, beat profit estimates for the second-consecutive quarter as the drugmaker's push into specialty treatments continued to pay off.
India's largest pharmaceutical firm posted a 13% rise in net income to 20.5 billion rupees ($274 million) for the quarter ended Sept. 30, compared to an average estimate of 16.44 billion rupees based on a Bloomberg survey of analysts. Revenue climbed 13% to 96.3 billion rupees, according to an exchange filing Tuesday. Total costs rose 10% to 75.6 billion rupees.
The better-than-expected financial results show Shanghvi is continuing to reap the rewards of his gamble on specialty drugs, from skin to cancer medicines, which grew 43% globally in the quarter compared to the same period last year.
“We remain steadfast in our focus on growing our overall business and simultaneously strengthening our global specialty portfolio,” Shanghvi said in a statement. “The recent launch of Winlevi in U.S. and Ilumya in Canada is a step forward in this direction,” he added, referring to Sun's acne and plaque psoriasis treatments.
The Mumbai-based drugmaker saw its take from branded formulations in India up 26%, accounting for a third of Sun's revenue. The U.S. market contributed close to another third of the company's sales and grew 8%.
Covid Treatments
Sun has also branched into Covid-19 treatments and is collaborating with Indian peers for local clinical trials of Merck & Co.'s promising molnupiravir pill indicated for mild Covid infections. It also signed a licensing agreement with Eli Lilly & Co. to manufacture and distribute baricitinib in India that's used in treating hospitalized Covid patients.
Sun's share price climbed 0.4% on Tuesday and has advanced 38% this year, outpacing the 26% rise of India's benchmark S&P BSE Sensex Index.
“The stock has performed well in the recent past gaining sharply after first quarter results and in the last few weeks with more data emerging on market share ramp up in key specialty assets in the U.S.,” AllianceBernstein analysts led by Nithya Balasubramanian wrote in an Oct. 20 report. “We remain bullish on Sun's ability to continue to scale up in specialty.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.